CD19+ Lymphoma, B-Cell

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Eureka Therapeutics
Eureka TherapeuticsCA - Emeryville
1 program
1
ET190L1-ARTEMIS™ T cells -iv low dosePhase 11 trial
Active Trials
NCT03895944UnknownEst. Dec 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Eureka TherapeuticsET190L1-ARTEMIS™ T cells -iv low dose

Clinical Trials (1)

NCT03895944Eureka TherapeuticsET190L1-ARTEMIS™ T cells -iv low dose

ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and Lymphoma

Start: Dec 2017Est. completion: Dec 2019
Phase 1Unknown

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space